Publications by authors named "Tamami Abe"

Background: Covert hepatic encephalopathy (CHE) leads to devastating outcomes in patients with cirrhosis. This study aims to elucidate the current management and future perspectives of CHE in Japan.

Methods: A questionnaire-based cross-sectional study was conducted among physicians involved in managing cirrhosis in Japan.

View Article and Find Full Text PDF

Background: Attenuation Imaging (ATI) and controlled attenuation parameter (CAP) are non-invasive ultrasound-based methods for diagnosing hepatic steatosis. However, reports on the clinical usefulness of ATI are limited. We aimed to compare the ability of ATI and CAP to diagnose hepatic steatosis with magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) as the reference standard.

View Article and Find Full Text PDF

We aimed to elucidate the value of ultrasound-based biomarkers for predicting the major life-threatening events in metabolic dysfunction-associated steatotic liver disease (MASLD). We established a prospective cohort of 279 patients who underwent two-dimensional shear wave elastography (2D-SWE), ultrasound-guided attenuation parameter (UGAP). An area under the curve analysis was performed to determine the cutoff values of liver stiffness measurements (LSM) by 2D-SWE and attenuation coefficient (AC) by UGAP for a moderate fibrosis and a moderate steatosis.

View Article and Find Full Text PDF

Background & Aims: Radiofrequency ablation (RFA) is the standard treatment for small hepatocellular carcinoma (HCC), specifically for tumors <3 cm in size and numbering fewer than three, excluding surgical candidates. Microwave ablation (MWA) is an innovative approach believed to have theoretical benefits over RFA; however, these advantages are yet to be empirically verified. Therefore, we evaluated and compared the effectiveness of MWA and RFA in managing HCC tumors up to 4 cm in size.

View Article and Find Full Text PDF

Background: Subharmonic-aided pressure estimation (SHAPE) is a technique for determining changes in ambient pressure. We aimed to analyze a novel SHAPE integrated into ultrasound diagnostic equipment to predict patients with liver cirrhosis at high risk of esophagogastric varices (EV).

Methods: This prospective study included 111 patients with liver cirrhosis diagnosed between 2020 and 2023.

View Article and Find Full Text PDF

Background: Steatotic liver disease, characterized by a combination of metabolic dysfunction, alcohol use, or specific etiologies, is a leading cause of chronic liver disease. However, the role of metabolic dysfunction in chronic liver disease with harmful alcohol use remains unclear. This study aimed to investigate factors associated with hepatic steatosis and fibrosis in patients with harmful alcohol use.

View Article and Find Full Text PDF
Article Synopsis
  • Durvalumab plus tremelimumab (Durva/Treme) is a newly approved treatment for unresectable hepatocellular carcinoma (u-HCC) in Japan, and researchers assessed its real-world outcomes.
  • A study evaluated 22 patients at Iwate Medical University who received Durva/Treme, comparing outcomes between those treated as first-line vs. later-line therapy.
  • Results showed no significant differences in progression-free survival, objective response rate, disease control rate, or adverse event incidence between the two groups, suggesting Durva/Treme is effective and safe for u-HCC patients regardless of treatment line.
View Article and Find Full Text PDF
Article Synopsis
  • * Conducted between October 2020 and October 2023, the study involved 89 u-HCC patients; the researchers used statistical models to analyze survival data and identify key prognostic factors.
  • * Results showed that patients with normal grip strength had significantly better overall survival rates compared to those with low grip strength, indicating that grip strength is a useful indicator of patient condition and treatment outcome.
View Article and Find Full Text PDF
Article Synopsis
  • - This study looked at how common acute pancreatitis is among patients with acute liver failure (ALF) and identified key features related to it.
  • - Researchers analyzed data from 83 ALF patients between 2011 and 2018 and found that 10.8% developed acute pancreatitis, which significantly lowered their survival rate.
  • - The model for end-stage liver disease score was identified as a potential risk marker for predicting acute pancreatitis in ALF patients, while factors like triglyceride levels, age, and gender showed no significant association.
View Article and Find Full Text PDF

Background And Aim: The study aims to determine the prognostic impact of obesity, sarcopenic obesity, and dynapenic obesity in patients with chronic liver disease.

Methods: This retrospective observational study enrolled patients with chronic hepatitis (n = 746) and liver cirrhosis (n = 434) without hepatocellular carcinoma at entry. The patients were evaluated for sarcopenia and obesity between April 2016 and April 2022.

View Article and Find Full Text PDF

The HIMALAYA trial is the first chemotherapeutic trial to demonstrate the efficacy of combined immune checkpoint inhibitors (ICIs) for unresectable hepatocellular carcinoma (u-HCC). The STRIDE regimen used in this trial consists of a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor and programmed cell death ligand 1 (PD-L1) inhibitor. Herein, we report two cases of ICI-colitis that occurred immediately after the initiation of the STRIDE regimen for u-HCC.

View Article and Find Full Text PDF

Prothrombin time (PT) is a key parameter for assessing the severity of liver disease. We present the case of a 37-year-old woman with severe acute liver injury due to autoimmune hepatitis. Although prednisolone drastically improved her hepatocyte function, her PT did not recover to the reference range.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on finding noninvasive methods to accurately assess hepatic steatosis (fat accumulation in the liver) due to the rising prevalence of nonalcoholic fatty liver disease.
  • - Researchers evaluated four different models using ultrasound (US) parameters to predict a minimum of 5% liver fat in patients with chronic liver disease (CLD), with MRI providing the reference for fat measurement.
  • - Results showed that the model incorporating UGAP, IBSC, and SNR parameters significantly improved the accuracy of diagnosing at least 5% steatosis compared to other models, achieving a maximum area under the curve (AUC) value of 0.96.
View Article and Find Full Text PDF

Aim: Hepatitis E virus (HEV) causes subclinical or acute self-limiting hepatitis. We surveyed the current seroprevalence and incidence of HEV infection among the general population in Iwate Prefecture, Japan, where the endemic infection is presumed to be low.

Methods: Between 2014 and 2016, we recruited individuals from Iwate Prefecture, Japan, who visited a general medical work-up program.

View Article and Find Full Text PDF

Aim: We aimed to establish a method that will identify patients at a high risk for progressive phenotype of fatty liver.

Methods: Patients with fatty liver who underwent liver biopsy between July 2008 and November 2019 were included as cohort 1, and those who underwent abdominal ultrasound screening examination by general physicians between August 2020 and May 2022 served as cohort 2. According to the definition of metabolic dysfunction-associated fatty liver (MAFLD), the subjects were classified by body mass index of ≥23, diabetes mellitus, and coexistence of two or more metabolic risk items.

View Article and Find Full Text PDF

Aim: We aimed to analyze the dispersion slope (DS) using shear wave dispersion (SWD) in patients with Fontan-associated liver disease (FALD) and to investigate its utility as a biomarker of disease progression.

Methods: This cross-sectional study enrolled 27 adults with FALD who underwent SWD, two-dimensional shear wave elastography (2D-SWE), transthoracic echocardiography, cardiac catheterization, or abdominal computed tomography (CT) from April 2019 to April 2021. According to CT findings, patients were divided into two groups: significant fibrosis and non-significant fibrosis.

View Article and Find Full Text PDF

Practitioners routinely perform intraoperative liver biopsies during laparoscopic sleeve gastrectomy (LSG) to evaluate nonalcoholic fatty liver disease (NAFLD). In some patients, hepatocyte ballooning, inflammation, and fibrosis without steatosis are observed, even in the absence of other etiologies. We call this finding indeterminable nonalcoholic steatohepatitis (Ind-NASH).

View Article and Find Full Text PDF
Article Synopsis
  • This study assessed the effectiveness of ultrasound-guided attenuation parameter (UGAP) in diagnosing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients, comparing it to other methods like attenuation imaging (ATI) and controlled attenuation parameter (CAP).
  • The analysis involved 105 NAFLD patients who underwent UGAP, ATI, CAP, and a liver biopsy on the same day, with UGAP showcasing a 100% success rate in obtaining results.
  • The findings revealed that UGAP provides accurate diagnostic information for grading liver fat content, with higher accuracy than CAP, and strong correlation with ATI measurements, indicating it’s a reliable tool for assessing hepatic steatosis severity.
View Article and Find Full Text PDF

We herein report two cases of locally advanced unresectable hepatocellular carcinoma (u-HCC) that were resected after achieving a radiological complete response to initially administered lenvatinib followed by transcatheter arterial chemoembolization (LEN-TACE sequential therapy). A 78-year-old woman and an 80-year-old man with HCC of Barcelona Clinic Liver Cancer classification stage C were treated for 15 and 14 months with lenvatinib, respectively. Both patients were subsequently treated with TACE, resulting in complete remission on imaging.

View Article and Find Full Text PDF

Background And Aims: We investigated the usefulness of combining two-dimensional shear wave elastography and the ultrasound-guided attenuation parameter for assessing the risk of progressive non-alcoholic steatohepatitis, defined as non-alcoholic steatohepatitis with a non-alcoholic fatty liver disease activity score of ≥4 and a fibrosis stage of ≥2.

Methods: This prospective study included 202 patients with non-alcoholic fatty liver disease who underwent two-dimensional shear wave elastography, ultrasound-guided attenuation parameter, vibration-controlled transient elastography, the controlled attenuation parameter, and liver biopsy on the same day. Patients were grouped according to liver stiffness measurement using two-dimensional shear wave elastography and the attenuation coefficient, assessed using the ultrasound-guided attenuation parameter: A, low liver stiffness measurement/low attenuation coefficient; B, low liver stiffness measurement/high attenuation coefficient; C, high liver stiffness measurement/low attenuation coefficient; and D, high liver stiffness measurement/high attenuation coefficient.

View Article and Find Full Text PDF

There is limited information regarding the oncological benefits of microwave ablation using Thermosphere technology for hepatocellular carcinoma. This study compared the overall survival and recurrence-free survival outcomes among patients with hepatocellular carcinoma after microwave ablation using Thermosphere technology and after radiofrequency ablation. Between December 2017 and August 2020, 410 patients with hepatocellular carcinoma (a single lesion that was ≤5 cm or ≤3 lesions that were ≤3 cm) underwent ablation at our institution.

View Article and Find Full Text PDF

Background And Aims: Acute liver failure (ALF) is a rare but dramatic clinical syndrome characterized by massive hepatic necrosis leading to multiorgan failure. It is difficult to predict the outcomes in patients with ALF using existing prognostic models. We aimed to analyze hepatic perfusion using contrast-enhanced ultrasound and Doppler ultrasound in patients with ALF and investigate its utility as a prognostic biomarker.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines how muscle strength and skeletal muscle mass relate to the survival of patients with unresectable hepatocellular carcinoma (HCC) who are treated with lenvatinib.
  • Researchers found that a significant number of patients had decreased grip strength (33.3%) and skeletal muscle index (34.9%), and those with normal grip strength had better overall survival compared to those with decreased grip strength.
  • The study concludes that apart from liver function, decreased grip strength is a key indicator of poor prognosis in HCC patients undergoing lenvatinib treatment.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionr8b1lqhmgbt6k73jbenh46ltpb31jv95): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once